ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer
Larry Altstiel has been a respected leader for over twenty years in the Alzheimers clinical research community, and we are delighted to welcome him to the ProMIS team, stated Gene Williams, ProMIS Chairman and CEO.
- Larry Altstiel has been a respected leader for over twenty years in the Alzheimers clinical research community, and we are delighted to welcome him to the ProMIS team, stated Gene Williams, ProMIS Chairman and CEO.
- ProMIS has shown compelling scientific rationale for the differentiation of PMN310 in Alzheimers disease according to Dr. Altstiel.
- ProMIS unique technology platform has also led to the generation of potentially differentiated therapies in ALS and other neurodegenerative diseases.
- Larry Altstiel, M.D., Ph.D. brings decades of medical expertise in neurodegenerative diseases and experience in the pharmaceutical industry.